Cargando…
Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
BACKGROUND: Due to economic constraints, cancer therapies are under close scrutiny by clinicians, pharmacists and payers alike. There is no published pharmacoeconomic evidence guiding the choice of first-line therapy for advanced renal cell carcinoma (RCC) in the Spanish setting. We aimed to develop...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856525/ https://www.ncbi.nlm.nih.gov/pubmed/24004638 http://dx.doi.org/10.1186/1471-2407-13-399 |